Navigation Links
Cancer Drug Safe for Late-Stage Pelvic Disease
Date:4/7/2010

Vorinostat can be used with radiotherapy in palliative care, study finds

WEDNESDAY, April 7 (HealthDay News) -- It's safe to use a new oral anti-cancer drug called vorinostat with short-term palliative radiation therapy in patients with advanced pelvic cancer, according to a phase 1 study.

Palliative therapy is used to help control symptoms in patients who can't be cured.

Radiation therapy is an effective palliative treatment to control pain and bleeding in patients with advanced pelvic cancer who aren't eligible for curative radiation therapy or surgery. Vorinostat -- a type of histone deacetylase (HDAC) inhibitor -- is believed to stop tumor growth by altering the expression of several genes necessary for cancer growth.

This study included 16 patients who received either 100 milligram, 200 mg, 300 mg, or 400 mg daily doses of vorinostat three hours before pelvic palliative radiation to 30 Gy in 3 Gy daily fractions over two weeks.

Nausea, diarrhea and anorexia were the most common side effects experienced by all the patients. Biological activity of vorinostat was detected in patients who received the lowest and highest levels of the drug. Most patients had an overall decrease in tumor size six weeks after they completed the combined treatment.

"These observations show that vorinostat can be safely combined with a standard palliative radiotherapy regimen to treat advanced pelvic cancer," wrote Prof. Anne H. Ree of Norwegian Radium Hospital in Oslo and colleagues.

"This study adds to mounting evidence supporting the use of HDAC inhibition in cancer therapy. These data encourage further examination of this class of molecularly targeted agents in clinical radiotherapy," they concluded.

The study was published online April 6 in The Lancet Oncology.

More information

The U.S. National Institutes of Health has more on palliative care.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, April 6, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New study implicates health care utilization, over biology, in colorectal cancer disparities
2. Mount Sinai study finds only a weak link between fruit and vegetable and reduced risk of cancer
3. Fruits, Veggies Have Modest Effect on Cancer Risk
4. Gene Mutations Up Risk for Cancer in Opposite Breast
5. Childhood cancer survivors may face shortened lifespan, study reveals
6. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
7. Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast
8. Childhood Cancer Survivors At Higher Odds of Early Death
9. Only women with Western Swedish breast cancer gene run higher risk of ovarian cancer
10. New investigation supports correlation between XMRV and prostate cancer
11. New Breast Cancer Book Offers Humor Filled Look at Being Thirty-Something, Single And Getting Through Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: